
Grifols, S.A. GRFS
€ 7.11
0.85%
Geschäftsbericht 2024
hinzugefügt 18.04.2026
Grifols, S.A. Langfristiger Schuldenstrom 2011-2026 | GRFS
Langfristiger Schuldenstrom Jährlich Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117 M | 107 M | 102 M | 48.6 M | 42.6 M | 44.4 M | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 117 M | 42.6 M | 76.9 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
45 M | $ 93.04 | -2.58 % | $ 27.2 B | ||
|
INmune Bio
INMB
|
623 K | $ 1.48 | -3.9 % | $ 36.6 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 22.79 | 1.95 % | $ 3.78 B | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.6 | 2.86 % | $ 5.93 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
294 K | $ 23.55 | 0.56 % | $ 3 B | ||
|
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
429 K | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
2.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 53.07 | 1.32 % | $ 4.77 B | ||
|
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.69 | 2.74 % | $ 450 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
208 K | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |